Brief: Lidds Says Analysis Of Tumors Confirms Depot Function Of NZ-Tlr9

Lidds AB

25/03/2020 07:33

March 25 (Reuters) - Lidds AB  LIDDS.ST :
    * REG-LIDDS ANNOUNCES POSITIVE PRECLINICAL DATA FOR
NANOZOLID®-TLR9 AGONIST PROJECT
    * LIDDS AB - IN VIVO EFFICACY IS AS GOOD AS WITH REPEATED
INJECTIONS OF STANDARD TLR9 AGONIST
    * LIDDS AB - PHARMACOKINETIC ANALYSIS OF TREATED TUMORS HAS
CONFIRMED DEPOT FUNCTION OF NZ-TLR9.
    * LIDDS AB - HAS PERFORMED PRECLINICAL STUDIES USING A TLR9
AGONIST FORMULATED WITH NANOZOLID® (NZ-TLR9) SHOWING THAT A
SINGLE NZ-TLR9 INJECTION IS REDUCING TUMOR GROWTH AND IMPROVES
SURVIVAL RATE

Source text for Eikon:  ID:nGNE5MT40x 
Further company coverage:  LIDDS.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))